VEGFA and age-related macular degeneration: Since increased VEGF-A levels are implicated in the pathogenesis, the current state of the art treatment for AMD and DR is the repeated intravitreal injection of anti-VEGF drugs like Bevacizumab (Avastin®), Ranibizumab (Lucentis®) and Aflibercept (Eylea®).